Bloom Energy's data-center power bet: huge demand, thin margin of safety
A Bloom Energy five-year double thesis focused on data-center distributed power, fuel-cell economics, backlog quality, margins, cash flow, and execution risk.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
20Results18Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
Bloom Energy: fast power promise, cash-flow proof gap
A Coverage Bootstrap Bloom Energy company evaluation covering fuel cells, data-center power demand, revenue growth, adjusted EBITDA, margins, project execution, cash flow, and risk controls.
OpenPhillips 66: a refining giant where cash flow still follows the cycle
Phillips 66 reported $132.4 billion of 2025 revenue and $5.0 billion of operating cash flow, but first-quarter 2026 cash flow turned negative and the thesis depends on refining margins, midstream stability, capital discipline and leverage through the cycle.
OpenEQIX: AI demand is exciting, but the data-center math has to beat the capital bill
Equinix reported FY2025 revenue of $9.2 billion, operating cash flow of $3.9 billion and Q1 2026 revenue of $2.4 billion. The thesis depends on interconnection demand, data-center utilization, power availability, debt capacity and capital efficiency.
OpenEOG: The shale cash machine still has to prove discipline after a stronger Q1
EOG reported FY2025 revenue of $22.6 billion, operating cash flow of $10.0 billion and Q1 2026 revenue of $6.9 billion. The thesis depends on commodity prices, drilling discipline, cost control, reserve quality and shareholder-return durability.
OpenFANG: Diamondback has Permian scale, but Q1 shows why shale still needs discipline
Diamondback reported FY2025 revenue of $15.0 billion, operating cash flow of $8.8 billion and Q1 2026 revenue of $4.2 billion. The thesis depends on Permian well productivity, commodity prices, capital spending, acquisition integration and shareholder-return d
OpenConstellation's AI power thesis: nuclear scarcity meets data-center demand
A Constellation five-year double thesis focused on clean firm power scarcity, nuclear fleet value, data-center PPAs, regulation, and acquisition execution.
OpenConstellation Energy: nuclear scarcity in the AI power race
A Coverage Bootstrap Constellation Energy company evaluation covering nuclear fleet economics, clean firm power, data-center PPAs, regulation, fleet reliability, acquisitions, and valuation risk.
OpenAIDX: OneTest has revenue growth, but the new Nasdaq float is dilution math
20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
OpenAIB: BlockchAIn's AI data-center pitch still runs through one power bill
BlockchAIn has a real 40 MW operating data center and an AI/HPC infrastructure pitch, but the latest filings show margin pressure, thin cash, heavy customer and energy-provider concentration, related-party control and non-binding pipeline claims.
OpenAIIA: the AI shell has cash, a clock, and no target yet
AI Infrastructure Acquisition Corp. is a newly public SPAC with $140.5 million in trust, $1.1 million of cash outside trust, no operating revenue, no announced target and an April 6, 2027 deadline. The current thesis is trust math, sponsor incentives and futur
OpenAmerican Electric Power: the data-center load rush now has a $78B utility bill
AEP has turned the utility growth story into a transmission-led data-center and industrial load story, lifting its 2026-2030 capital plan to $78 billion while preserving 2026 guidance. The investment case now depends on rate recovery, balance-sheet funding and
OpenAnfield Energy Has a 106% Uranium IRR Story - And One Huge Catch
Anfield Energy's updated PEA makes the Shootaring mill restart look explosive, but AEC is still a no-revenue uranium developer that has to clear permits, capital, reserves, construction, and first production.
OpenAdvanced Biomed: The No-Revenue Biotech That Just Swerved Into AI
Advanced Biomed has historical cancer-diagnostics technology, but the latest filings show no product revenue, a reverse split, a short-term loan, a subsidiary divestiture, and an April 2026 pivot into AI.
OpenAditxt: The Biotech Roll-Up Fighting Nasdaq Before It Fights Disease
Aditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
OpenAdaptive Biotechnologies: Can clonoSEQ outrun the cash-burn clock?
Adaptive's clonoSEQ MRD business is finally showing scale, but the proof gate is whether test volume, reimbursement, pharma milestones, and operating leverage can absorb cash burn and the OrbiMed revenue-interest obligation.
OpenAcacia Research: the cash-rich puzzle box Wall Street can misprice
Acacia is a public acquisition/operator vehicle with energy wells, industrial printers, Deflecto manufacturing, patent licensing, life-sciences remnants, and a large capital base. The question is whether those parts compound per-share value or bury it in compl
OpenAclarion: the $19M cash pile chasing a tiny Nociscan revenue line
Aclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reim
OpenAbbott (ABT): the diabetes-device machine now carrying a $20.6B cancer-diagnostics bet
Abbott's Medical Devices engine, led by diabetes care, is doing the heavy lifting while Nutrition weakens and the Exact Sciences acquisition adds cancer-diagnostics upside, debt, and integration risk.
OpenAgilent Technologies (A): the lab-workflow compounder still waiting for the cycle to turn
Agilent's CrossLab mix and cash generation point to a durable lab-workflow franchise, but the open question is whether service and consumables strength can outrun instrument-cycle volatility.
Open